|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZFYVE27 |
Gene summary for ZFYVE27 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZFYVE27 | Gene ID | 118813 |
| Gene name | zinc finger FYVE-type containing 27 | |
| Gene Alias | PROTRUDIN | |
| Cytomap | 10q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q5T4F4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 118813 | ZFYVE27 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.00e-08 | 3.59e-01 | -0.1954 |
| 118813 | ZFYVE27 | HTA11_411_2000001011 | Human | Colorectum | SER | 3.47e-02 | 6.50e-01 | -0.2602 |
| 118813 | ZFYVE27 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.81e-02 | 2.96e-01 | -0.059 |
| 118813 | ZFYVE27 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 8.59e-10 | 3.85e-01 | 0.3859 |
| 118813 | ZFYVE27 | A015-C-106 | Human | Colorectum | FAP | 2.80e-02 | -1.23e-01 | -0.0511 |
| 118813 | ZFYVE27 | A002-C-116 | Human | Colorectum | FAP | 3.77e-04 | -1.41e-01 | -0.0452 |
| 118813 | ZFYVE27 | LZE4T | Human | Esophagus | ESCC | 1.10e-02 | 1.09e-01 | 0.0811 |
| 118813 | ZFYVE27 | LZE8T | Human | Esophagus | ESCC | 5.11e-05 | 1.78e-01 | 0.067 |
| 118813 | ZFYVE27 | LZE20T | Human | Esophagus | ESCC | 2.58e-05 | 1.97e-01 | 0.0662 |
| 118813 | ZFYVE27 | LZE24T | Human | Esophagus | ESCC | 5.77e-15 | 3.51e-01 | 0.0596 |
| 118813 | ZFYVE27 | LZE6T | Human | Esophagus | ESCC | 4.18e-02 | 1.33e-01 | 0.0845 |
| 118813 | ZFYVE27 | P1T-E | Human | Esophagus | ESCC | 1.14e-07 | 3.60e-01 | 0.0875 |
| 118813 | ZFYVE27 | P2T-E | Human | Esophagus | ESCC | 4.05e-31 | 5.44e-01 | 0.1177 |
| 118813 | ZFYVE27 | P4T-E | Human | Esophagus | ESCC | 1.35e-22 | 4.64e-01 | 0.1323 |
| 118813 | ZFYVE27 | P5T-E | Human | Esophagus | ESCC | 1.86e-09 | 2.18e-01 | 0.1327 |
| 118813 | ZFYVE27 | P8T-E | Human | Esophagus | ESCC | 7.55e-17 | 2.79e-01 | 0.0889 |
| 118813 | ZFYVE27 | P9T-E | Human | Esophagus | ESCC | 1.24e-08 | 1.93e-01 | 0.1131 |
| 118813 | ZFYVE27 | P10T-E | Human | Esophagus | ESCC | 7.12e-09 | 1.76e-01 | 0.116 |
| 118813 | ZFYVE27 | P11T-E | Human | Esophagus | ESCC | 3.43e-13 | 4.06e-01 | 0.1426 |
| 118813 | ZFYVE27 | P12T-E | Human | Esophagus | ESCC | 4.02e-25 | 3.94e-01 | 0.1122 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00507697 | Esophagus | ESCC | positive regulation of neurogenesis | 131/8552 | 225/18723 | 9.71e-05 | 6.90e-04 | 131 |
| GO:003030710 | Esophagus | ESCC | positive regulation of cell growth | 100/8552 | 166/18723 | 1.07e-04 | 7.55e-04 | 100 |
| GO:00083619 | Esophagus | ESCC | regulation of cell size | 107/8552 | 181/18723 | 1.81e-04 | 1.16e-03 | 107 |
| GO:006156415 | Esophagus | ESCC | axon development | 251/8552 | 467/18723 | 2.41e-04 | 1.49e-03 | 251 |
| GO:001097516 | Esophagus | ESCC | regulation of neuron projection development | 240/8552 | 445/18723 | 2.48e-04 | 1.53e-03 | 240 |
| GO:00519606 | Esophagus | ESCC | regulation of nervous system development | 237/8552 | 443/18723 | 5.02e-04 | 2.78e-03 | 237 |
| GO:006056010 | Esophagus | ESCC | developmental growth involved in morphogenesis | 131/8552 | 234/18723 | 9.28e-04 | 4.73e-03 | 131 |
| GO:00717865 | Esophagus | ESCC | endoplasmic reticulum tubular network organization | 15/8552 | 18/18723 | 1.20e-03 | 5.88e-03 | 15 |
| GO:00519625 | Esophagus | ESCC | positive regulation of nervous system development | 149/8552 | 272/18723 | 1.50e-03 | 7.06e-03 | 149 |
| GO:00457738 | Esophagus | ESCC | positive regulation of axon extension | 29/8552 | 42/18723 | 1.87e-03 | 8.46e-03 | 29 |
| GO:000740915 | Esophagus | ESCC | axonogenesis | 219/8552 | 418/18723 | 3.14e-03 | 1.31e-02 | 219 |
| GO:00507728 | Esophagus | ESCC | positive regulation of axonogenesis | 48/8552 | 79/18723 | 4.93e-03 | 1.89e-02 | 48 |
| GO:004858810 | Esophagus | ESCC | developmental cell growth | 125/8552 | 234/18723 | 1.01e-02 | 3.46e-02 | 125 |
| GO:004592717 | Esophagus | ESCC | positive regulation of growth | 137/8552 | 259/18723 | 1.13e-02 | 3.80e-02 | 137 |
| GO:0048011 | Esophagus | ESCC | neurotrophin TRK receptor signaling pathway | 17/8552 | 24/18723 | 1.13e-02 | 3.81e-02 | 17 |
| GO:007265921 | Liver | HCC | protein localization to plasma membrane | 177/7958 | 284/18723 | 1.02e-11 | 4.18e-10 | 177 |
| GO:199077821 | Liver | HCC | protein localization to cell periphery | 200/7958 | 333/18723 | 6.07e-11 | 2.23e-09 | 200 |
| GO:001604921 | Liver | HCC | cell growth | 269/7958 | 482/18723 | 1.84e-09 | 5.35e-08 | 269 |
| GO:000702911 | Liver | HCC | endoplasmic reticulum organization | 64/7958 | 87/18723 | 3.92e-09 | 1.04e-07 | 64 |
| GO:003253522 | Liver | HCC | regulation of cellular component size | 217/7958 | 383/18723 | 1.28e-08 | 3.14e-07 | 217 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
| hsa041441 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
| hsa041442 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
| hsa041443 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
| hsa041444 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
| hsa041445 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
| hsa041446 | Colorectum | FAP | Endocytosis | 78/1404 | 251/8465 | 6.20e-09 | 2.96e-07 | 1.80e-07 | 78 |
| hsa041447 | Colorectum | FAP | Endocytosis | 78/1404 | 251/8465 | 6.20e-09 | 2.96e-07 | 1.80e-07 | 78 |
| hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0414427 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| hsa04144112 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZFYVE27 | SNV | Missense_Mutation | novel | c.739C>T | p.Pro247Ser | p.P247S | Q5T4F4 | protein_coding | tolerated(0.39) | benign(0.075) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| ZFYVE27 | SNV | Missense_Mutation | rs758277807 | c.531N>C | p.Glu177Asp | p.E177D | Q5T4F4 | protein_coding | tolerated(0.41) | benign(0.068) | TCGA-C8-A1HJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZFYVE27 | insertion | Frame_Shift_Ins | novel | c.829_830insTCAATAATAATAATTGTAATAAAAA | p.Pro277LeufsTer16 | p.P277Lfs*16 | Q5T4F4 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
| ZFYVE27 | SNV | Missense_Mutation | novel | c.686N>T | p.Ser229Phe | p.S229F | Q5T4F4 | protein_coding | tolerated(0.79) | benign(0.007) | TCGA-C5-A1BJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ZFYVE27 | SNV | Missense_Mutation | rs368842487 | c.1067C>T | p.Thr356Met | p.T356M | Q5T4F4 | protein_coding | tolerated(0.07) | possibly_damaging(0.534) | TCGA-AA-3697-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ZFYVE27 | SNV | Missense_Mutation | rs772972223 | c.782N>T | p.Thr261Met | p.T261M | Q5T4F4 | protein_coding | deleterious(0.04) | possibly_damaging(0.87) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ZFYVE27 | SNV | Missense_Mutation | c.361N>A | p.Glu121Lys | p.E121K | Q5T4F4 | protein_coding | tolerated(0.07) | benign(0.178) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
| ZFYVE27 | SNV | Missense_Mutation | c.598N>T | p.Pro200Ser | p.P200S | Q5T4F4 | protein_coding | tolerated(0.1) | probably_damaging(0.998) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
| ZFYVE27 | SNV | Missense_Mutation | rs751379469 | c.538N>A | p.Val180Ile | p.V180I | Q5T4F4 | protein_coding | tolerated(0.12) | benign(0) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZFYVE27 | SNV | Missense_Mutation | c.838N>A | p.Val280Met | p.V280M | Q5T4F4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |